As reported by the BBC, The European Court of Justice has banned the issuing of patents for embryonic stem cell research.
The research has been banned on ethical grounds as it involves the destruction of human embryos.
Stem cell research involves extracting human embryonic stem cells from surplus vitro fertilised eggs donated after fertility treatment. The cells are then modified and injected into patients. These cells are a useful tool for repairing and regenerating diseased organs and tissues.
The European Court has stated that “scientific research entailing the use of human embryos cannot access the protection of patent law” and that it is unethical to profit from what it sees as the fundamentals of human life.
The case was originally raised by Greenpeace against scientist, Oliver Brustle, who was investigating the use of stem cells to treat neurological diseases such as Parkinson’s.
So, whilst there are no restrictions on human embryonic stem cell research in Europe, it will now be extremely difficult to get patent approval for any new discoveries that are made as a result of this research.
The ruling is a real blow to the commercial development of such products within the European Union. The ruling effectively means that any stem cell research technique invented by scientists working in the EU can now be easily and legally copied by rival scientists.
Lastly, there is also a fear that this type of research could be pushed elsewhere as Pharmaceutical companies in the EU will be less inclined to seek involvement as they are now unable to safeguard their investment.
Azilect already has approval by the FDA to treat symptoms of the neurological disorder (such as shaking, stiffness, impaired balance). However, Teva are now seeking an extension of Azilect’s label. However, it is being scrutinized by the FDA as they question it’s effectiveness in slowing down the progression of the disease.
Scepticism regarding the drug stems from results from Teva’s latest trial – the disease appeared to deteriorate more slowly in patients who started taking the drug early in the progression of the disease, rather than later. However, whilst the 1mg dose slowed progression, the 2mg dose did not. This has brought questions about the trial results.
As reported by the BBC, a new treatment for the advanced and aggressive form of prostate cancer has been developed by Scientists at Queen’s University.
The drug will now be tested in a second phase, combines chemotherapy treatments with two doses of a radioactive chemical.
Speaking of the new treatment, Consultant and Senior Lecturer in Clinical Oncology, Dr O’Sullivan stated,
“This is a significant development in the fight against prostate cancer. While this combination treatment still has to go to phase two of trials, to know that this combination is safe and feasible as a treatment is a huge step forward.”
Pharmaceutical-jobs.com has reported on a joint Anglo-Russian pharmaceutical company which is expected to create a large amount of jobs in the UK.
Combining British expertise and international capital with the funding from the Russian Corporation of Nanotechnologies, the project, which was devised by Celtic Pharma in London and is called Pro Bono Bio, is the first pharmaceutical company to have clear humanitarian target’s from the outset. Pro Bono Bio has already begun marketing drugs, with a treatment for osteoarthritis already on the market and two other drugs soon to be released to combat skin disorders. A treatment for haemophilia is also in the pipeline.
The drugs will initially be marketed in Europe, with European and Russian manufacturers initially being used as sources, before two plants, one in the UK and one near Moscow, are built to make the drugs. These plants are expected to create jobs and be able to supply a global market for the company.
Clinical development is the largest growing section of the global biomarkers market, which is expected to reach $34 billion by 2017, reports pharmatimes.com.
Annual growth of over a quarter leading up to 2017 is expected in biomarker applications in clinical drug development, though the high costs of the trials hampers the overall market growth, which means smaller businesses aren’t involving themselves in the sector. Despite this, the biomarker applications sector is growing quickly, particularly as 90% of drugs fail in clinical trials.
Biomarkers allow detection of reasons drugs may fail, such as toxicity, in early stage trials which allows for significant savings in the long term. Oncology and cardiology are expected to be the two areas in which biomarkers are most extensively used as drugs fail in clinical trials more often for these therapy types. They can also be used to assess patient’s susceptibility to illness, such as the risk of a stable patient suffering coronary issues, for example a stroke.
The trial, which has been running since 2007, is evaluating the effectiveness of the breast cancer drug Tyverb in four different combinations, following surgery. The patients in the trial receive either Tyverb, Roche’s established drug Herceptin, Herceptin followed by Tyverb or both drugs.
An interim report has indicated that the patients only receiving Tyverb are not demonstrating any improvement compared to Herceptin, so that arm of the trial has been discontinued. Those who are halting their treatment are to discuss other options with trial physicians. 8,400 patients are taking part in the study, and the remaining three trials are to continue as normal.
Jonathan Hart-Smith at CK Clinical is looking for a Director of Health Outcomes to join his client based in London.
As Director of Health Outcomes you will play a pivotal role in guiding the organisation, providing a strategic insight and understanding of theirs client’s and stakeholders needs.
As Director of Health Outcomes you will also be responsible for developing important relationships with instrument authors and key opinion leaders and make recommendations on instrument selection and validation. You will support the Sales and Operations streams and participate in bed defences.
In addition, you will represent the company at scientific conferences, webinars and be recognized as an authority in the industry.
The ideal candidate:
To be considered for this Director of Health Outcomes position, you will possess comprehensive knowledge of the regulatory requirements in the EU and US for patient reported outcomes. In addition, this role demands candidates with a broad and diverse understanding of many different therapeutic areas.
How to apply:
For more information or to apply for this Health Outcomes Director role, please contact Jonathan on 01438 743 047 or email email@example.com.
CK Clinical is proud to announce that our ClinicalJobs app for iPhone is now available to download from iTunes!
CK Clinical is always looking for new and innovative ways to make the job hunting experience as easy and as enjoyable as possible for our candidates. We would therefore like to introduce to our new free ClinicalJobs iPhone app.
The ClinicalJobs app for iPhone will help take the hassle out of searching for your next job in science. By simply downloading the app you can search, shortlist and apply for the latest science jobs directly from your mobile – anytime, anywhere.
Features of the ClinicalJobs app include:
Search and apply for jobs 24/7
Real time updates of jobs.
Find jobs across different disciplines including: Clinical/Clinical QA, Clinical R&D, Clinical Operations, Nurses, Data management, SAS, Biostatistics, Regulatory Affairs, Pharmacovigilance, Drug Safety, Medical Information, Medical Affairs, Health Outcomes, Pharmaceutical Medics, Medical Writing
Search for jobs near you.
Add selected jobs to your shortlist and apply at a time that suits you.
Access the latest industry news and careers advice